Cochrane · systematic review · CD004421
Taxanes for adjuvant treatment of early breast cancer
Willson, ML, Burke, L, Ferguson, T, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 3 · 50%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTaxane‐containing chemotherapy vs any chemotherapy without taxane for early breast cancer
Population: women with early breast cancer (operable, stages I to IIIA)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Taxane‐containing chemotherapy vs any chemotherapy without taxane | HR 0.87 [0.83, 0.92] | 27 studies · 39180 participants | High |
Disease‐free progression Taxane‐containing chemotherapy vs any chemotherapy without taxane | HR 0.88 [0.85, 0.92] | 29 studies · 41909 participants | High |
Quality of life Taxane‐containing chemotherapy vs any chemotherapy without taxane | no estimate extracted | 7 studies · 7 participants | Low Downgraded: risk of bias, imprecision |
Febrile neutropenia Taxane‐containing chemotherapy vs any chemotherapy without taxane | OR 1.43 [0.89, 2.31] | 23 studies · 34154 participants | Moderate Downgraded: inconsistency |
Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) Taxane‐containing chemotherapy vs any chemotherapy without taxane | OR 6.89 [3.23, 14.71] | 22 studies · 31033 participants | Moderate Downgraded: inconsistency |
Cardiotoxicity (including grade 3/4 and congestive cardiac failure) Taxane‐containing chemotherapy vs any chemotherapy without taxane | OR 0.87 [0.56, 1.33] | 23 studies · 32894 participants | Moderate Downgraded: imprecision |
Comparison
Population: patients with early breast cancer (operable, stages I to IIIA)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality ( | HR 0.81 [0.75, 0.88] | 11 studies · 18304 participants | High |
Risk of recurrence ( | HR 0.81 | 11 studies · 19943 participants | High |
Quality of life2 ( | no estimate extracted | NR | No studies |
Cardiotoxicity ( | RR 0.9 [0.53, 1.54] | 6 studies · 11577 participants | Moderate Downgraded: imprecision, inconsistency |
Febrile neutropaenia ( | RR 2.32 [1.1, 4.49] | 7 studies · 10224 participants | Moderate Downgraded: imprecision, inconsistency |
Nausea and/or vomiting ( | RR 0.58 [0.42, 0.79] | 5 studies · 6087 participants | High |